ME/CFS, also known as myalgic encephalomyelitis/chronic fatigue syndrome, is a debilitating illness that affects millions of people worldwide. The center at Columbia was at the forefront of research and treatment for ME/CFS, but now it has been shut down due to lack of funding.
This closure is a devastating blow to the ME/CFS community, as it leaves patients without crucial resources and researchers without a dedicated space to continue their important work. The center was known for its innovative approaches to studying ME/CFS, including the use of advanced imaging techniques and cutting-edge treatment options.
Patients who relied on the center for their care are now left in limbo, unsure of where to turn for help. Many are concerned that without the center’s expertise, their treatment options will be limited and their quality of life will suffer.
Advocates for ME/CFS research are calling for increased funding and support for centers like the one at Columbia, so that important work can continue and patients can receive the care they need. ME/CFS is a complex and poorly understood illness, and research is crucial to finding effective treatments and ultimately a cure.
As the ME/CFS community grapples with the loss of the center at Columbia, there is a renewed sense of urgency to support research and advocacy efforts. Patients deserve access to high-quality care and researchers need the resources to continue their vital work. The closure of the center is a stark reminder of the challenges facing those with ME/CFS, but it also serves as a call to action to ensure that their voices are heard and their needs are met. The Trump administration’s cuts to Columbia University’s funding have led to the shutdown of a large research program, as one of its top researchers informed STAT’s Isabella Cueto. The center is now unable to purchase supplies to continue research or fill vacant positions, despite Columbia allowing the center to continue paying salaries for workers supported by the slashed grants. Three crucial projects involving thousands of patients are at risk, including a genetics study, research on infections leading to ME/CFS, and an analysis of patients’ self-reported symptoms compared to biological markers.
Interestingly, this isn’t the first time that the administration’s cuts at Columbia have impacted programs focused on chronic diseases, despite claims that it is a major priority. The situation highlights the challenges faced by research institutions when funding is cut, jeopardizing important scientific advancements and medical breakthroughs.
On a different note, California lawmakers are taking steps to remove ultra-processed foods from school lunches by 2032, aiming to improve both physical and mental health among students. The proposed bill introduces the first legal definition of ultra-processed foods in the country, focusing on industrially produced foods with additives like artificial flavors, preservatives, and synthetic dyes. This move reflects states stepping in where the federal government may be lacking, emphasizing the importance of healthy eating habits in schools.
In other news, there are updates on various topics, including an anti-abortion lawyer being pushed out of the FDA due to pressure from a Republican senator, the Trump administration extending the opioid emergency as fentanyl deaths decrease, and the FDA warning Africa’s largest drugmaker, Aspen Pharmacare, over sterility issues at a key plant. These developments underscore the diverse and evolving landscape of healthcare and policy in the United States and beyond.
